FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199951353> ?p ?o ?g. }

• W3199951353 endingPage "105426" @default.
• W3199951353 startingPage "105426" @default.
• W3199951353 abstract "Women with premenstrual dysphoric disorder (PMDD) experience mood symptoms related to the increase in progesterone and the neuroactive steroid allopregnanolone. Our hypothesis is that allopregnanolone is the symptom provoking factor. The rationale for the present study was to treat PMDD patients with the GABAA receptor modulating steroid antagonist, sepranolone (isoallopregnanolone). Patients (n = 206) with PMDD from 12 European centers were randomized in a parallel double-blind study and treated with placebo, sepranolone 10 mg and 16 mg. Patients administered sepranolone subcutaneously every 48 h during the 14 premenstrual days of three consecutive menstrual cycles. After obtaining informed consent, the PMDD diagnosis was confirmed according to DSM-5 and verified with two menstrual cycles of daily symptom ratings using the Daily Record of Severity of Problems (DRSP) scale in an eDiary. Inclusion and exclusion criteria stipulated that the women should be essentially healthy, not pregnant, have no ongoing psychiatric disorder or take interfering medications, and have regular menstrual cycles. The study's primary endpoint was the Total symptom score (Sum21, the score for all 21 symptom questions in the DRSP). In the prespecified statistical analysis the average score of the 5 worst premenstrual days in treatment cycles 2 and 3 were subtracted from the corresponding average score in the two diagnostic cycles. The treatment effects were tested using analysis of variance in a hierarchal order starting with the combined active sepranolone treatments vs. placebo. The prespecified analysis of Sum21 showed a large treatment effect of all three treatments but no statistically significant difference to placebo. However, the ratings of distress showed a significant treatment effect of sepranolone compared to placebo (p = 0.037) and the ratings of impairment showed a trend to greater treatment effect of sepranolone compared to placebo. Many women with PMDD had symptoms during a longer period than the late luteal phase. It has previously been shown that 9 premenstrual days may be more representative for comparison of PMDD symptom periods than the 5 worst premenstrual days. A post hoc analysis was undertaken in the per protocol population investigating the treatment effect during 9 premenstrual days in the third treatment cycle. The Sum21 results of this analysis showed that the sepranolone 10 mg was significantly better than placebo (p = 0.008). Similar significant treatment effects were found for the impairment and distress scores. A significantly larger number of individuals experienced no or minimal symptoms (Sum21 <42 points) with the 10 mg sepranolone treatment compared to placebo (p = 0.020). The results indicate that there is an attenuating effect by sepranolone on symptoms, impairment, and distress in women with PMDD especially by the 10 mg dosage. Sepranolone was well tolerated, and no safety concerns were identified." @default.
• W3199951353 created "2021-09-27" @default.
• W3199951353 creator A5027736827 @default.
• W3199951353 creator A5032251281 @default.
• W3199951353 creator A5032338044 @default.
• W3199951353 creator A5033369161 @default.
• W3199951353 creator A5053480244 @default.
• W3199951353 creator A5054647726 @default.
• W3199951353 creator A5072230774 @default.
• W3199951353 creator A5078092878 @default.
• W3199951353 date "2021-11-01" @default.
• W3199951353 modified "2023-10-08" @default.
• W3199951353 title "A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder" @default.
• W3199951353 cites W1561083615 @default.
• W3199951353 cites W195754633 @default.
• W3199951353 cites W1965774807 @default.
• W3199951353 cites W1980882938 @default.
• W3199951353 cites W199080563 @default.
• W3199951353 cites W1998495772 @default.
• W3199951353 cites W2001391111 @default.
• W3199951353 cites W2012453718 @default.
• W3199951353 cites W2013061047 @default.
• W3199951353 cites W2013589717 @default.
• W3199951353 cites W2015682236 @default.
• W3199951353 cites W2017457726 @default.
• W3199951353 cites W2017460642 @default.
• W3199951353 cites W2024556146 @default.
• W3199951353 cites W2040015157 @default.
• W3199951353 cites W2040115686 @default.
• W3199951353 cites W2044509639 @default.
• W3199951353 cites W2046110224 @default.
• W3199951353 cites W2056179366 @default.
• W3199951353 cites W2065556700 @default.
• W3199951353 cites W2068298897 @default.
• W3199951353 cites W2072245904 @default.
• W3199951353 cites W2076714793 @default.
• W3199951353 cites W2076845765 @default.
• W3199951353 cites W2104104178 @default.
• W3199951353 cites W2106709706 @default.
• W3199951353 cites W2132726881 @default.
• W3199951353 cites W2140896143 @default.
• W3199951353 cites W2141498968 @default.
• W3199951353 cites W2143552278 @default.
• W3199951353 cites W2146894298 @default.
• W3199951353 cites W2147682916 @default.
• W3199951353 cites W2159304905 @default.
• W3199951353 cites W2164867212 @default.
• W3199951353 cites W2592974289 @default.
• W3199951353 cites W2784139627 @default.
• W3199951353 cites W2908444276 @default.
• W3199951353 doi "https://doi.org/10.1016/j.psyneuen.2021.105426" @default.
• W3199951353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34597899" @default.
• W3199951353 hasPublicationYear "2021" @default.
• W3199951353 type Work @default.
• W3199951353 sameAs 3199951353 @default.
• W3199951353 citedByCount "20" @default.
• W3199951353 countsByYear W31999513532022 @default.
• W3199951353 countsByYear W31999513532023 @default.
• W3199951353 crossrefType "journal-article" @default.
• W3199951353 hasAuthorship W3199951353A5027736827 @default.
• W3199951353 hasAuthorship W3199951353A5032251281 @default.
• W3199951353 hasAuthorship W3199951353A5032338044 @default.
• W3199951353 hasAuthorship W3199951353A5033369161 @default.
• W3199951353 hasAuthorship W3199951353A5053480244 @default.
• W3199951353 hasAuthorship W3199951353A5054647726 @default.
• W3199951353 hasAuthorship W3199951353A5072230774 @default.
• W3199951353 hasAuthorship W3199951353A5078092878 @default.
• W3199951353 hasBestOaLocation W31999513531 @default.
• W3199951353 hasConcept C118552586 @default.
• W3199951353 hasConcept C126322002 @default.
• W3199951353 hasConcept C142724271 @default.
• W3199951353 hasConcept C15744967 @default.
• W3199951353 hasConcept C168258287 @default.
• W3199951353 hasConcept C168563851 @default.
• W3199951353 hasConcept C170493617 @default.
• W3199951353 hasConcept C204787440 @default.
• W3199951353 hasConcept C27081682 @default.
• W3199951353 hasConcept C2776801781 @default.
• W3199951353 hasConcept C2778015638 @default.
• W3199951353 hasConcept C2778338918 @default.
• W3199951353 hasConcept C2779058012 @default.
• W3199951353 hasConcept C2779771394 @default.
• W3199951353 hasConcept C2780733359 @default.
• W3199951353 hasConcept C44796713 @default.
• W3199951353 hasConcept C71315377 @default.
• W3199951353 hasConcept C71924100 @default.
• W3199951353 hasConceptScore W3199951353C118552586 @default.
• W3199951353 hasConceptScore W3199951353C126322002 @default.
• W3199951353 hasConceptScore W3199951353C142724271 @default.
• W3199951353 hasConceptScore W3199951353C15744967 @default.
• W3199951353 hasConceptScore W3199951353C168258287 @default.
• W3199951353 hasConceptScore W3199951353C168563851 @default.
• W3199951353 hasConceptScore W3199951353C170493617 @default.
• W3199951353 hasConceptScore W3199951353C204787440 @default.
• W3199951353 hasConceptScore W3199951353C27081682 @default.
• W3199951353 hasConceptScore W3199951353C2776801781 @default.
• W3199951353 hasConceptScore W3199951353C2778015638 @default.
• W3199951353 hasConceptScore W3199951353C2778338918 @default.

• next